Well shit, is this in the USA?  The FDA has basically banned high potency statins due to side effects. Are you that incompetent that you don't know regulations?  And you trust your doctors?

FDA announces new safety recommendations for high-dose simvastatin June 2011

http://www.onlinejacc.org/content/69/22/2696?sso=1&sso_redirect_count=2&access_token=

Volume 69, Issue 22, June 2017 DOI: 10.1016/j.jacc.2017.03.585

PDF Article

Trends in Use of High-Intensity Statin Therapy After Myocardial Infarction, 2011 to 2014

Robert S. Rosenson, Michael E. Farkouh, Matthew Mefford, Vera Bittner, Todd M. Brown, Ben Taylor, Keri L. Monda, Hong Zhao, Yuling Dai, Paul Muntner

This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click the login link or the subscribe link in the top menu above to access this article.

Author + information

Central Illustration

• Download figure
• Open in new tab
• Download powerpoint

Abstract

Background Data prior to 2011 suggest that a low percentage of patients hospitalized for acute coronary syndromes filled high-intensity statin prescriptions upon discharge. Black-box warnings, generic availability of atorvastatin, and updated guidelines may have resulted in a change in high-intensity statin use.

Objectives The aim of this study was to examine trends and predictors of high-intensity statin use following hospital discharge for myocardial infarction (MI) between 2011 and 2014.

Methods Secular trends in high-intensity statin use following hospital discharge for MI were analyzed among patients 19 to 64 years of age with commercial health insurance in the MarketScan database (n = 42,893) and 66 to 75 years of age with U.S. government health insurance through Medicare (n = 75,096). Patients filling statin prescriptions within 30 days of discharge were included. High-intensity statins included atorvastatin 40 or 80 mg and rosuvastatin 20 or 40 mg.

Results The percentage of beneficiaries whose first statin prescriptions filled following hospital discharge for MI were for high-intensity doses increased from 33.5% in January through March 2011 to 71.7% in October through November 2014 in MarketScan and from 24.8% to 57.5% in Medicare. Increases in high-intensity statin use following hospital discharge occurred over this period among patients initiating treatment (30.6% to 72.0% in MarketScan and 21.1% to 58.8% in Medicare) and those taking low- or moderate-intensity statins prior to hospitalization (from 27.8% to 62.3% in MarketScan and from 12.6% to 45.1% in Medicare). In 2014, factors associated with filling high-intensity statin prescriptions included male sex, filling beta-blocker and antiplatelet agent prescriptions, and attending cardiac rehabilitation within 30 days following discharge.

Conclusions The use of high-intensity statins following hospitalization for MI increased progressively from 2011 through 2014.